Comparing Entyvio vs Rinvoq
| Entyvio (vedolizumab) | Rinvoq (upadacitinib) |
|
|---|
| Entyvio (vedolizumab) | Rinvoq (upadacitinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
|
|||||||||||||||
| More about Entyvio (vedolizumab) | More about Rinvoq (upadacitinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Entyvio has an average rating of 6.2 out of 10 from a total of 162 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 28% reported a negative effect. |
Rinvoq has an average rating of 7.0 out of 10 from a total of 224 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Entyvio side effects |
View all Rinvoq side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Entyvio prices |
View all Rinvoq prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other vedolizumab brands include: Entyvio Pen | Other upadacitinib brands include: Rinvoq LQ | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
600 hours |
14 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 164 drugs are known to interact with Entyvio:
|
A total of 597 drugs are known to interact with Rinvoq:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
May 20, 2014 |
August 16, 2019 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.